Skip to main content
. 2021 May 6;35(6):681–690. doi: 10.1007/s40263-021-00817-w

Fig. 1.

Fig. 1

Study flow. Schematic flowchart showing the number of participants and the procedure of assigning patients to recombinant human erythropoietin or placebo and follow-up to 18 months of corrected age. Preterm infants with grade I–IV intraventricular hemorrhage were enrolled in the study. IVH intraventricular hemorrhage, rhEPO recombinant human erythropoietin